Skip to main content
Erschienen in: Infection 6/2015

01.12.2015 | Original Paper

High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia

verfasst von: Eric Batard, Nathalie Lecadet, Nicolas Goffinet, Jean-Benoit Hardouin, Didier Lepelletier, Gilles Potel, Emmanuel Montassier, The CEFPU1 Study Group

Erschienen in: Infection | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

Fluoroquinolones and 3rd-generation cephalosporins that are prescribed for pneumonia may be avoided and replaced by a penicillin in some cases. We aimed to determine if the proportion of patients treated for pneumonia with a cephalosporin, a fluoroquinolone or both varies among Emergency Departments (EDs), and to estimate the proportion of avoidable prescriptions.

Methods

This was a retrospective study of patients treated for pneumonia in eight French EDs, and subsequently hospitalized in non-ICU wards. Third-generation cephalosporins or respiratory fluoroquinolones were presumed unavoidable if they met both criteria: (1) age ≥65 years or comorbid condition; and (2) allergy or intolerance to penicillin, or failure of penicillin, or previous treatment with penicillin, or for fluoroquinolones only, suspected legionellosis.

Results

We included 832 patients. Thirty-four percent (95 % CI, 31–38 %) of patients were treated with a cephalosporin, a respiratory fluoroquinolone or both (range among EDs 19–44 %). Four EDs were independent risk factors for prescription of a cephalosporin, a fluoroquinolone or both [adjusted OR, 2.27 (1.64–3.15)], as were immune compromise [aOR 2.54 (1.56–4.14)], antibacterial therapy started before arrival in the ED [aOR 3.32 (2.30–4.81)], REA-ICU class III or IV [aOR 1.93 (1.15–3.23)], PSI class V [aOR 1.49 (1.00–2.20)], fluid ressuscitation [aOR 3.98 (2.49–6.43)] and non-invasive ventilation in the ED [aOR, 7.18 (1.7–50.1)]. Treatment with a cephalosporin, a fluoroquinolone or both was avoidable in 67 % (62–73 %) of patients.

Conclusion

Cephalosporins and fluoroquinolones use in pneumonia is highly variable among EDs. The majority of these prescriptions are avoidable. Antibiotic stewardship programs should be implemented to restrict their use in EDs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kaier K, Frank U, Hagist C, Conrad A, Meyer E. The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother. 2009;63:609–14.CrossRefPubMed Kaier K, Frank U, Hagist C, Conrad A, Meyer E. The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother. 2009;63:609–14.CrossRefPubMed
2.
Zurück zum Zitat Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control. 2005;33:326–32.CrossRefPubMed Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control. 2005;33:326–32.CrossRefPubMed
3.
Zurück zum Zitat Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163–7.CrossRefPubMed Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163–7.CrossRefPubMed
4.
Zurück zum Zitat Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897–902.CrossRefPubMed Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897–902.CrossRefPubMed
5.
Zurück zum Zitat Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish Elhajji FW, et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol. 2012;74:171–9.PubMedCentralCrossRefPubMed Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish Elhajji FW, et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol. 2012;74:171–9.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–20.CrossRefPubMed Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–20.CrossRefPubMed
7.
Zurück zum Zitat Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341–5.CrossRefPubMed Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341–5.CrossRefPubMed
8.
Zurück zum Zitat Roson B, Carratala J, Tubau F, Dorca J, Linares J, Pallares R, et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin–clavulanate and ceftriaxone. Microb Drug Resist. 2001;7:85–96.CrossRefPubMed Roson B, Carratala J, Tubau F, Dorca J, Linares J, Pallares R, et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin–clavulanate and ceftriaxone. Microb Drug Resist. 2001;7:85–96.CrossRefPubMed
9.
Zurück zum Zitat Sanchez ME, Gomez J, Gomez Vargas J, Banos V, Ruiz Gomez J, Munoz L, et al. Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Rev Esp Quimioter. 1998;11:132–8.PubMed Sanchez ME, Gomez J, Gomez Vargas J, Banos V, Ruiz Gomez J, Munoz L, et al. Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Rev Esp Quimioter. 1998;11:132–8.PubMed
10.
Zurück zum Zitat Paterson DL, Playford EG. Should third-generation cephalosporins be the empirical treatment of choice for severe community-acquired pneumonia in adults? Med J Aust. 1998;168:344–8.PubMed Paterson DL, Playford EG. Should third-generation cephalosporins be the empirical treatment of choice for severe community-acquired pneumonia in adults? Med J Aust. 1998;168:344–8.PubMed
11.
Zurück zum Zitat Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–59.CrossRefPubMed Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–59.CrossRefPubMed
12.
Zurück zum Zitat Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.CrossRefPubMed Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.CrossRefPubMed
13.
Zurück zum Zitat Goffinet N, Lecadet N, Cousin M, Peron C, Hardouin JB, Batard E, et al. Increasing use of third-generation cephalosporins for pneumonia in the emergency department: may some prescriptions be avoided? Eur J Clin Microbiol Infect Dis. 2014;33:1095–9.CrossRefPubMed Goffinet N, Lecadet N, Cousin M, Peron C, Hardouin JB, Batard E, et al. Increasing use of third-generation cephalosporins for pneumonia in the emergency department: may some prescriptions be avoided? Eur J Clin Microbiol Infect Dis. 2014;33:1095–9.CrossRefPubMed
14.
Zurück zum Zitat Blasi F, Garau J, Medina J, Avila M, McBride K, Ostermann H. Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Resp Res. 2013;14:44.CrossRef Blasi F, Garau J, Medina J, Avila M, McBride K, Ostermann H. Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Resp Res. 2013;14:44.CrossRef
15.
Zurück zum Zitat Neuman MI, Ting SA, Meydani A, Mansbach JM, Camargo CA Jr. National study of antibiotic use in emergency department visits for pneumonia, 1993 through 2008. Acad Emerg Med. 2012;19:562–8.PubMedCentralCrossRefPubMed Neuman MI, Ting SA, Meydani A, Mansbach JM, Camargo CA Jr. National study of antibiotic use in emergency department visits for pneumonia, 1993 through 2008. Acad Emerg Med. 2012;19:562–8.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Trinh HT, Hoang PH, Cardona-Morrell M, Nguyen HT, Vu DH, Dong PT, et al. Antibiotic therapy for inpatients with community-acquired pneumonia in a developing country. Pharmacoepidemiol Drug Saf. 2014;24:129–36.CrossRefPubMed Trinh HT, Hoang PH, Cardona-Morrell M, Nguyen HT, Vu DH, Dong PT, et al. Antibiotic therapy for inpatients with community-acquired pneumonia in a developing country. Pharmacoepidemiol Drug Saf. 2014;24:129–36.CrossRefPubMed
17.
Zurück zum Zitat Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33:1065–79.PubMedCentralCrossRefPubMed Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33:1065–79.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Kohlhammer Y, Raspe H, Marre R, Suttorp N, Welte T, Schafer T, et al. Antibiotic treatment of community acquired pneumonia varies widely across Germany. J Infect. 2007;54:446–53.CrossRefPubMed Kohlhammer Y, Raspe H, Marre R, Suttorp N, Welte T, Schafer T, et al. Antibiotic treatment of community acquired pneumonia varies widely across Germany. J Infect. 2007;54:446–53.CrossRefPubMed
19.
Zurück zum Zitat Koller D, Hoffmann F, Maier W, Tholen K, Windt R, Glaeske G. Variation in antibiotic prescriptions: is area deprivation an explanation? Analysis of 1.2 million children in Germany. Infection. 2013;41:121–7.CrossRefPubMed Koller D, Hoffmann F, Maier W, Tholen K, Windt R, Glaeske G. Variation in antibiotic prescriptions: is area deprivation an explanation? Analysis of 1.2 million children in Germany. Infection. 2013;41:121–7.CrossRefPubMed
21.
Zurück zum Zitat Sorde R, Falco V, Lowak M, Domingo E, Ferrer A, Burgos J, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med. 2011;171:166–72.CrossRefPubMed Sorde R, Falco V, Lowak M, Domingo E, Ferrer A, Burgos J, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med. 2011;171:166–72.CrossRefPubMed
22.
Zurück zum Zitat Matta M, Kerneis S, Day N, Lescat M, Hoi AB, Varon E, et al. Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients? Clin Microbiol Infect. 2010;16:1389–93.CrossRefPubMed Matta M, Kerneis S, Day N, Lescat M, Hoi AB, Varon E, et al. Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients? Clin Microbiol Infect. 2010;16:1389–93.CrossRefPubMed
23.
Zurück zum Zitat Engel MF, van Velzen M, Hoepelman AI, Thijsen S, Oosterheert JJ. Positive urinary antigen tests for Streptococcus pneumoniae in community-acquired pneumonia: a 7-year retrospective evaluation of health care cost and treatment consequences. Eur J Clin Microbiol Infect Dis. 2013;32:485–92.CrossRefPubMed Engel MF, van Velzen M, Hoepelman AI, Thijsen S, Oosterheert JJ. Positive urinary antigen tests for Streptococcus pneumoniae in community-acquired pneumonia: a 7-year retrospective evaluation of health care cost and treatment consequences. Eur J Clin Microbiol Infect Dis. 2013;32:485–92.CrossRefPubMed
24.
Zurück zum Zitat Duchene E, Montassier E, Boutoille D, Caillon J, Potel G, Batard E. Why is antimicrobial de-escalation under-prescribed for urinary tract infections? Infection. 2013;41:211–4.CrossRefPubMed Duchene E, Montassier E, Boutoille D, Caillon J, Potel G, Batard E. Why is antimicrobial de-escalation under-prescribed for urinary tract infections? Infection. 2013;41:211–4.CrossRefPubMed
25.
Zurück zum Zitat Khasawneh FA, Karim A, Mahmood T, Ahmed S, Jaffri SF, Tate ME, et al. Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome. Infection. 2014;42:829–34.CrossRefPubMed Khasawneh FA, Karim A, Mahmood T, Ahmed S, Jaffri SF, Tate ME, et al. Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome. Infection. 2014;42:829–34.CrossRefPubMed
27.
Zurück zum Zitat Borde JP, Litterst S, Ruhnke M, Feik R, Hubner J, deWith K, et al. Implementing an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a 200-bed community hospital in Germany. Infection. 2015;43:45–50.CrossRefPubMed Borde JP, Litterst S, Ruhnke M, Feik R, Hubner J, deWith K, et al. Implementing an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a 200-bed community hospital in Germany. Infection. 2015;43:45–50.CrossRefPubMed
28.
Zurück zum Zitat May L, Cosgrove S, L’Archeveque M, Talan DA, Payne P, Jordan J, et al. A call to action for antimicrobial stewardship in the emergency department: approaches and strategies. Ann Emerg Med. 2013;62:69–77.CrossRefPubMed May L, Cosgrove S, L’Archeveque M, Talan DA, Payne P, Jordan J, et al. A call to action for antimicrobial stewardship in the emergency department: approaches and strategies. Ann Emerg Med. 2013;62:69–77.CrossRefPubMed
29.
Zurück zum Zitat Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:1–55. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:1–55.
30.
Zurück zum Zitat Singanayagam A, Chalmers JD. Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respir Med. 2013;1:653–62.CrossRefPubMed Singanayagam A, Chalmers JD. Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respir Med. 2013;1:653–62.CrossRefPubMed
Metadaten
Titel
High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia
verfasst von
Eric Batard
Nathalie Lecadet
Nicolas Goffinet
Jean-Benoit Hardouin
Didier Lepelletier
Gilles Potel
Emmanuel Montassier
The CEFPU1 Study Group
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 6/2015
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0793-7

Weitere Artikel der Ausgabe 6/2015

Infection 6/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.